Home » Intra-Cellular Therapies Receives License From Bristol-Myers Squibb
Intra-Cellular Therapies Receives License From Bristol-Myers Squibb
Intra-Cellular Therapies (ITI), a privately held biopharmaceutical company focusing on the development of new therapeutics for neuropsychiatric and neurodegenerative disorders, announced that it has been granted an exclusive, worldwide license to a family of preclinical compounds from Bristol-Myers Squibb.
()a href="http://www.biospace.com/news_story.cfm?StoryID=20233420&full=1" target="_blank">BioSpace
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May